NCT06019000 is a Phase 2 clinical trial of CYR-064 in Hyposmia, sponsored by Cyrano Therapeutics, Inc..

Who is sponsoring NCT06019000?

NCT06019000 is sponsored by Cyrano Therapeutics, Inc..

What drugs are being tested in NCT06019000?

Interventions in NCT06019000: CYR-064.

Is NCT06019000 still recruiting?

NCT06019000 is currently completed. Last updated 18 February 2026.

Last reviewed 2026-02-18 · How we verify

NCT06019000

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of CYR-064 Versus Placebo in Patients.

Completed Phase 2 Last updated 18 February 2026

What this trial tests

Phase 2 trial testing CYR-064 in Hyposmia in 151 participants. Completed in 21 November 2025.

Timeline

26 September 2023

Primary endpoint
11 November 2025

21 November 2025

Quick facts

Lead sponsor	Cyrano Therapeutics, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	151
Start date	26 September 2023
Primary completion	11 November 2025
Estimated completion	21 November 2025
Sites	14 locations across United States

Drugs / interventions tested

CYR-064 — full drug profile →

Conditions studied

Hyposmia — all drugs for Hyposmia →

Sponsor

Cyrano Therapeutics, Inc.

Who can join

Adults 18 to 70, any sex, with Hyposmia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hyposmia

Currently open trials in the same condition.

NCT06733636 — Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults · NA · recruiting
NCT06817499 — Treatment of Olfactory Dysfunction Using Vagus Nerve Stimulation · NA · active not recruiting
NCT05364125 — Olfactory Training on Smell Dysfunction Patients in HK · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06019000 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cyrano Therapeutics, Inc.
Last refreshed: 18 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06019000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing